
Cryo-EM structure of active GPR65 leadXpro has just elucidated the world’s first structure of a proton-sensing GPCR target.
leadXpro Timeline
Latest updates about leadXpro
Cumulus Oncology and leadXpro Announce Collaboration to Develop Small Molecules against Novel Cancer-Focused GPCR Targets
Cumulus Oncology and leadXpro Announce Collaboration.
Resulting IP will be licensed into a newly created Cumulus company
SCIENTIFIC WEBINAR
Early drug discovery requires an interdisciplinary approach with a sophisticated interplay between empirical methods and rational design. Amongst the different therapeutic modalities, orally available small molecules are a major pillar for safe treatment of acute and chronic diseases.
RaQualia Pharma and leadXpro Announce Collaboration to Accelerate Drug Discovery on Intractable Membrane Protein Targets
In this collaboration, leadXpro will establish robust protocols and workflows to facilitate the rapid determination